市場調查報告書
商品編碼
1394977
細胞解離市場規模 - 按產品(酵素解、非酵素解)、應用(組織解離、細胞分離)、最終用戶、全球預測,2023 - 2032 年Cell Dissociation Market Size - By Product (Enzymatic Dissociation, Non-Enzymatic Dissociation), Application (Tissue Dissociation, Cell Detachment), End-user, Global Forecast, 2023 - 2032 |
預計從 2023 年到 2032 年,細胞解離市場規模的CAGR將達到 15.3%。對細胞療法和再生醫學的需求不斷成長,推動了對多種有效細胞解離方法的需求。最近,研發活動不斷取得進步,特別是在幹細胞研究和生物技術方面。
慢性病盛行率的上升和對個人化醫療的需求不斷成長將推動對用於治療目的的分離細胞的需求。此外,實驗室技術和技術的不斷發展以及生命科學研究投資的不斷增加也將推動更有效的解離方法開發的創新。例如,2022年3月,LevitasBio推出了LeviPrep(TM)和LeviSelect(TM)產品線,以增強人類和小鼠組織和細胞樣本的處理,以進行高級生物研究。
細胞分離市場分為產品、應用、最終用戶和地區。
根據產品,預計 2023 年至 2032 年非酶解領域的行業佔有率將達到 16.2% 的CAGR。這一成長可歸因於對溫和高效解離方法的需求不斷增加、細胞壓力減少以及對敏感細胞類型。非酵素方法也因其與各種細胞培養應用和工作流程的兼容性而受到重視。
細胞分離應用領域預計將佔據相當大的收入佔有率,在整個分析期間CAGR為 16.5%。這是由於細胞培養過程中對高效且可重複的分離方法的需求不斷成長。生物技術、再生醫學和細胞療法的應用不斷增加將促進該領域的成長。
從地區來看,歐洲細胞解離產業規模預計從 2023 年到 2032 年將快速成長。這種成長可歸因於細胞研究的不斷進步、生物技術應用範圍的擴大以及生命科學研究的大量資金。此外,一些歐洲國家對創新醫療解決方案的日益關注以及對個人化醫療的高需求將推動該地區對細胞分離技術的需求。
Cell dissociation market size is projected to record 15.3% CAGR from 2023 to 2032. The increasing demand for cell-based therapies and regenerative medicine is driving the need for several efficient cell dissociation methods. Of late, there have been rising advancements in R&D activities, particularly in stem cell research and biotechnology.
The rising prevalence of chronic diseases and the growing need for personalized medicine will drive the demand for dissociated cells for therapeutic purposes. Additionally, the continuous evolution of laboratory techniques and technologies along with the growing investments in life sciences research will also push innovations in the development of more effective dissociation methods. For instance, in March 2022, LevitasBio introduced the LeviPrep™ and LeviSelect™ product lines to enhance the processing of human and mouse tissue and cell samples for advanced biological research.
The cell dissociation market is segregated into product, application, end-user, and region.
Based on product, the industry share from the non-enzymatic dissociation segment is projected to depict 16.2% CAGR from 2023 to 2032. The growth can be attributed to the increasing demand for gentle and efficient dissociation methods, reduced cell stress, and the suitability for sensitive cell types. The non-enzymatic approach is also gaining prominence for its compatibility with various cell culture applications and workflows.
The cell detachment application segment is estimated to account for sizeable revenue share, exhibiting 16.5% CAGR throughout the analysis period. This is owing to the rising demand for efficient and reproducible detachment methods in cell culture processes. The increasing application in biotechnology, regenerative medicine, and cell-based therapies will boost the segment growth.
Regionally, the Europe cell dissociation industry size is slated to grow at rapid pace from 2023 to 2032. The growth can be ascribed to the increasing advancements in cell-based research, expanding application scope in biotechnology, and hefty funding for life sciences research. Additionally, the rising focus of several European countries on innovative healthcare solutions along with the high demand for personalized medicine will fuel the demand for cell dissociation technologies in the region.